Arch Biopartners Inc V.ARCH

Calgary herald

[2019champs]

https://calgaryherald.com/news/local-news/made-in-calgary-drug-to-treat-covid-19-organ-inflammation-joins-national-trial

[Arbourmark]

Although the news was positive it was grey in my opinion and the markets need more clarity. I for one was expecting more meat in the news release and in this news article from Calgary sun.  The market clearly demonstrated yesterday that it requires more answers from mana age meant. 1. How much is this phase 3 trial going to cost? $50-$100M is standard. 2. Does Arch need to raise

[stocksarefun]

I could not agree more. The words Phase 3 aren't mentioned in either article, financial post or Calgary Herald. No timeline for when peer review will be complete, and no mention of US participation in trial, FDA anything, or uplisting plans.   I obviously hope it's not the case, but I think the pattern breaking yesterday signals to me that it likely could continue a push

[Riverfolk]

1. How much is this phase 3 trial going to cost? $50-$100M is standard. 2. Does Arch need to raise capital, if so how much? Is there dilution coming? 3. Is the Canadian Government going to participate in funding, if so how much? We know they kicked in $6.7M for phase 2. , LSALT Peptide (LSALT and “Metablok”) will enter the Canadian Treatments for COVID-19 (CATCO) human trial, a multi-centre

[Arbourmark]

Riverfolk, don't get me wrong I am very bullish about the company but they drafted a very grey news release that leaves more questions then answers which I feel will have negative pressure on momentum until we get answers. You are inserting your opinions here not facts. Yes typical phase 3 trials run from $50M to $100M but that a huge amount of money and not too mention a very wide range

[Riverfolk]

The press release states clearly the following: LSALT is the first novel therapeutic to join the Canadian Treatments for COVID-19 trial, a multi-centre adaptive, randomized, open-label, controlled clinical trial involving sixty-five hospitals across Canada CATCO is being conducted in conjunction with the World Health Organization’s SOLIDARITY trial, in collaboration with countries around

[Arbourmark]

I am happy that is your interpretation but I respectfully state the market has a different view at this time and needs clarity. If the markets agreed with your comments below and based on numerous posts how undervalued we are for a phase 2 company announcing a fully funded phase 3 study ($50m to $100m), would this have not caused the share price to spike to a minimum $600M to $1B market cap

[GoldenArm]

The market is in a bad mood lately but the companies results are very good such that a bigger human trial is needed. 55,000 shares traded so far today isn't a hell of a lot of shares. It tells me the speculators are out, weak hands sold the small amount of shares they had. 55k shares traded doesn't speak for the market.

[Riverfolk]

The Market is being extremely inefficient, I cant argue that at all. Just as it was when the governement funding for phase II was announced. The biosciences Sector is extremely difficult to understand and for most they get emotional in times what should be jovial. The data from Phase II is currently waiting on the publication, which will derisk further for those who want to enter with funds etc

[fourbarrels]

My understanding is this will cost the government $30k per patient so $9 to $10 million for the Covid application trial. Lovely!!